Company Overview - West Pharmaceutical Services, Inc. (WST) is a leading global healthcare company specializing in the design, manufacture, and sale of innovative containment and delivery systems for injectable drugs and healthcare products, with a market cap of approximately $19.2 billion [1][2] Stock Performance - The stock has decreased by 23.6% from its 52-week high of $348.90 reached in January, while over the past three months, shares have gained 3.1%, underperforming the Health Care Select Sector SPDR Fund (XLV), which gained 12.5% during the same period [3] - Year-to-date, WST has experienced an 18.7% decline, lagging behind XLV's 12% gains, and has dipped 19.4% over the past 52 weeks compared to XLV's 10.6% gain [4] - The stock has been trading above the 50-day moving average since early June and above the 200-day moving average since mid-September, although it has shown some fluctuations recently [4] Market Challenges - The stock's decline in 2025 is attributed to investor concerns regarding its outlook and operational headwinds, including broader pricing pressures, tariff-related cost issues, and inventory destocking by customers, which have negatively impacted near-term growth prospects [5] Competitive Landscape - In comparison, rival Thermo Fisher Scientific Inc. (TMO) has outperformed WST, gaining 7.8% over the past 52 weeks and 9.6% year-to-date [6] - Despite WST's underperformance, it holds a consensus rating of "Strong Buy" from 17 analysts, with a mean price target of $345.36, indicating a potential upside of 29.6% [6]